[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-201538-105":59,"doc-detail-201538-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","poster-abstracts-34th-international-prostate-cancer-update","Poster Abstracts - 34th International Prostate Cancer Update","","34th INTERNATIONAL PROSTATE CANCER UPDATE 2024 poster abstracts compile a set of clinical and translational research reports focused on prostate cancer diagnosis, treatment response, and predictive biomarkers. Topics include real-world outcomes by risk group, imaging and detection performance of PSMA-targeted radiopharmaceuticals, liquid biopsy approaches using tumor-associated ctDNA, genomic and molecular predictors of recurrence or adverse pathology, and therapeutic strategy updates across multiple trials and patient subgroups. The collection also covers management considerations such as rash incidence with apalutamide and clinical outcomes tied to testosterone nadir, PSA kinetics, and prior therapies.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/poster-abstracts-34th-international-prostate-cancer-update/201538/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/poster-abstracts-34th-international-prostate-cancer-update/201538.png","ImageObject",300,407,{"name":92,"@type":93},"Tawan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-16","2026-09-04",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"Do the abstracts include information about biomarkers and predictive tests?","Question",{"text":112,"@type":113},"Yes. The abstracts cover liquid biopsy targets such as ctDNA fragments and genomic classifier or mutation-related predictors of adverse pathology and outcomes.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},201538,1788535216,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":121,"read_time":136,"preview_page_count":4},2336475104042,"https://ap-avatar.wpscdn.com/avatar/22000c4c32af1715be0?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786537525561427321","34 th INTERNATIONAL PROSTATE CANCER UPDATETM  \nFebruary 11-14, 2024  \nPoster Abstracts  \nCONTENTS  \nAbstract 001 ..............................................................................................................................4  \nReal-World Clinical Outcomes by Risk Classification in Medicare Patients with Localized Prostate Cancer  \nTreated with Radical Prostatectomy  \nAbstract 002 .............................................................................................................................. 5  \nThe Forsvall Double Needle – A Future Needle Design Aiming to Improve Tissue Collection in Prostate  \nBiopsy  \nAbstract 003 .............................................................................................................................. 6  \nTestosterone Nadir and Clinical Outcomes In Patients Treated With Triptorelin Pamoate: A Retrospective  \nPooled Analysis Of Three Phase III Studies  \nAbstract 004 .............................................................................................................................. 7  \nPerformance Of FDA-Approved PSMA-Targeted Radiopharmaceuticals for The Detection Of Recurrent  \nProstate Cancer: A Systematic Literature Review  \nAbstract 005 .............................................................................................................................. 8  \nPhysical Isolation of Tumor-Associated CtDNA Fragments For Novel Prostate Cancer Liquid Biopsy  \nAbstract 006 .............................................................................................................................. 9  \nMYB Exhibits Racially Disparate Expression and Clinicopathologic Association In Prostate  \nCancer: Significance As A Predictor Of Biochemical Recurrence  \nAbstract 007 ............................................................................................................................ 10  \nTreatment Of Metastatic Castrate-Resistant Prostate Cancer Patient with Two Cycles Of 67Cu SAR  \nbisPSMA (8 GBq) Leads To Undetectable PSA Level: A Case Repor  \nAbstract 008 ............................................................................................................................ 11  \nEvaluating the mtDNA Copy Number in Prostate Cancer Samples  \nAbstract 009 ............................................................................................................................ 12  \nImpact Of a Rash Management Guide On Incidence And Severity Of Rash With Apalutamide: Experience  \nfrom The Apa-RP Study In High-Risk Localized Prostate Cancer  \nAbstract 010 ............................................................................................................................ 13  \nEffect Of Rapid Ultra-Low Prostate-Specific Antigen Decline (UL PSA) In TITAN Patients (pts) With  \nMetastatic Castration-Sensitive Prostate Cancer (mCSPC) who Received Apalutamide (APA) Plus  \nAndrogen Deprivation Therapy (ADT)  \nAbstract 011 ............................................................................................................................ 14  \nThe Effect of Prior Docetaxel (DOC) Treatment On Efficacy And Safety Of Apalutamide (APA) Plus  \nAndrogen Deprivation Therapy (ADT) In Patients (pts) With Metastatic Castration-Sensitive Prostate  \nCancer (mCSPC) From TITAN  \nAbstract 012 ............................................................................................................................ 15  \nNiraparib (NIRA) With Abiraterone Acetate Plus Prednisone (AAP) As First-Line (1L) Therapy In Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair (HRR) Gene Alterations: Three-Year Update And Final Analysis (FA) Of MAGNITUDE  \nPoster Abstracts – [34th International Prostate Cancer Update |](34th International Prostate Cancer Update | www.grandroundsinurology.com | 2)[ www.grandroundsinurology.com](34th International Prostate Cancer Update | www.grandroundsinurology.com |","cbCaityJKu9RDXqj","https://ap.wps.com/l/cbCaityJKu9RDXqj","pdf",2412619,28,"English","# Abstract 001\n## Real-World Clinical Outcomes by Risk Classification in Medicare Patients with Localized Prostate Cancer Treated with Radical Prostatectomy\n# Abstract 002\n## The Forsvall Double Needle – A Future Needle Design Aiming to Improve Tissue Collection in Prostate Biopsy\n# Abstract 003\n## Testosterone Nadir and Clinical Outcomes In Patients Treated With Triptorelin Pamoate: A Retrospective Pooled Analysis Of Three Phase III Studies\n# Abstract 004\n## Performance Of FDA-Approved PSMA-Targeted Radiopharmaceuticals for The Detection Of Recurrent Prostate Cancer: A Systematic Literature Review\n# Abstract 005\n## Physical Isolation of Tumor-Associated CtDNA Fragments For Novel Prostate Cancer Liquid Biopsy\n# Abstract 006\n## MYB Exhibits Racially Disparate Expression and Clinicopathologic Association In Prostate Cancer: Significance As A Predictor Of Biochemical Recurrence\n# Abstract 007\n## Treatment Of Metastatic Castrate-Resistant Prostate Cancer Patient with Two Cycles Of 67Cu SAR bisPSMA (8 GBq) Leads To Undetectable PSA Level: A Case Report","[{\"question\":\"Do the abstracts include information about biomarkers and predictive tests?\",\"answer\":\"Yes. The abstracts cover liquid biopsy targets such as ctDNA fragments and genomic classifier or mutation-related predictors of adverse pathology and outcomes.\"}]","Poster Abstracts - 34th International Prostate Cancer Update | PDF",71]